Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Shares Climb 11 Percent on Narrowed Q2 Loss, Bio-Rad Sale

NEW YORK (GenomeWeb News) - Ciphergen today said second-quarter losses narrowed despite a 24-percent drop in second-quarter revenue.
 
The narrowed loss together with news that Bio-Rad will acquire its proteomics instrument business caused shares in Ciphergen to climb 11 percent, or $.11, to $1.09 in mid-afternoon trading.
 
Ciphergen reported $5.3 million in revenues for the quarter ended June 30, down from $6.9 million during the same quarter a year ago.
 
Ciphergen’s R&D expenses for the quarter declined 21 percent to $2.9 million from $3.6 million during the same period a year ago.
 
The company’s net loss shrank to $7.7 million from $9.3 million in the year-ago period.
 
As of June 30, Ciphergen had $20.6 million in cash, cash equivalents, and short-term investments.
The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.